



Office of Long-Term Living (OLTL) Updates

Long-Term Services and Supports (LTSS) Subcommittee Meeting

June 4, 2025

Presenter: Juliet Marsala, Deputy Secretary



Pennsylvania
Department of Human Services

Agenda

- OLTL Updates
 - Procurement Updates
 - Recent OLTL Communications
 - Revalidation Enrollment Reminders
 - American Rescue Plan Act (ARPA) Reporting Reminder
 - Statewide Preferred Drug List (PDL)



▶ OLTL Procurement Updates

■ Procurement Updates

– Community HealthChoices (CHC) Request for Applications (RFA)

- On August 22, 2024, the Department of Human Services (DHS) announced the applicants selected for agreement negotiations for the CHC Program Re-Procurement
- The CHC RFA is currently in a stay. All activity pertaining to the RFA has ceased, and no timeline can be shared at this time.
- The CHC program will continue to operate under the current CHC-Managed Care Organizations (MCOs) and agreements until further notice.
- **All questions regarding the RFA and its contents should be directed to Procurement via the resource account RA-pwrfaquestions@pa.gov.**



Recent OLTL Communications

- Operations Memorandum (Ops Memo) number 2025-07, **Denial Notices and Complaint and Grievance Reviews Ops Memo**, was posted to the [public site](#) and [Community HealthChoices \(CHC\) Extranet](#) with an issue date of May 22, 2025.
 - This Ops Memo provides additional clarification related to denial notices, in-person review requirements, and requirements for Complaint and Grievance review committees.
 - The memo clarifies that when a CHC-MCO issues a denial notice or a Complaint or Grievance decision notice, **the CHC-MCO is not required to include the name of the individual who made the decision to deny services or participated in the review committee**. Instead, the CHC-MCO should include a description of the individual's pertinent professional background, experience, and qualifications.
 - **CHC-MCOs must also maintain a written record that identifies the individual making the determination** and must make that information available upon request by the participant or department.

➤ Recent OLTL Communications (cont.)

- The Pennsylvania Department of Aging (PDA) offers a "[Caregiver Support Program](#)," which provides tools, information, and support to caregivers.
 - The program aims to alleviate the stresses associated with caregiving by focusing on the well-being of the caregiver, providing access to respite care, addressing the need for formal and informal supports, and providing financial reimbursement for out-of-pocket costs associated with caregiving-related services and supplies.
- On Wednesday, May 28, 2025, PDA launched the [PA Carekit](#), a collection of tools, information, and resources to address key challenges in the caregiver journey.
 - As part of Aging Our Way, PA, PDA was tasked with creating a dynamic, interactive, and comprehensive “caregiver toolkit” to address the key challenges faced by informal, unpaid caregivers and provide practical solutions and resources to support their entire caregiving journey.
 - An OLTL ListServ was released on June 2, 2025, that provides additional information on the Carekit, which includes a shareable one-page flier.
 - PDA has been invited to demo the PA Carekit at a future LTSS meeting.

➤ Provider Enrollment Reminders

- **Revalidation:** Please review your enrollment revalidation dates and ensure timely revalidation.
- **Provider Enrollment Profiles:** Update enrollment profiles ongoing.
- **Department of Health (DOH) Provider Licensure:** DOH licensure renewals are required for ongoing Medicaid enrollment. If there is a lapse, then the provider will be terminated from OLTL Medicaid Enrollment. A valid license is a qualification requirement for OLTL programs.

Provider Enrollment Team: RA-HCBSEnProv@pa.gov

Provider Support Team: RA-ProviderOperation@pa.gov

OLTL Provider Operations: 1-800-932-0939

➤ ARPA Reporting Reminder

- On April 16, 2025, OLTL communicated via ListServ, a reminder to providers of the requirement to report the use of ARPA of 2021 funding.
 - DHS' OLTL requires providers who received supplemental funding from the ARPA to report on their use of the funding and was due on Friday, May 30, 2025.
 - ARPA funding disbursements subject to this reporting requirement include:
 - Home and Community-Based Services (HCBS) Quality Improvement Funding
 - Act 2022-54 COVID-19 Relief Funding
- Failure to submit a report may result in the recovery of funding through collection activities, audits, or legal action.



➤ Statewide Preferred Drug List (PDL)

- The DHS maintains a [Statewide PDL](#) to ensure that Medical Assistance (MA) program beneficiaries in the Fee-for-Service (FFS) and HealthChoices/CHC-MCO delivery systems have access to clinically effective pharmaceutical care with an emphasis on quality, safety, and optimal results from the drugs that are prescribed for them.
 - The Statewide PDL is updated annually but does not preclude beneficiaries from getting new drugs that come to market as long as they meet Centers for Medicare & Medicaid Services (CMS) criteria for a Medicaid covered drug.
 - Drugs that fall into a class on the Statewide PDL are generally designated as non-preferred until they are reviewed by the Pharmacy and Therapeutics Committee.
 - These drugs remain available to Medicaid beneficiaries through the prior authorization process.

Statewide PDL – Current Treatment Agents

- The current obesity treatment agents are as follows:

OBESITY TREATMENT AGENTS

Preferred Agents	Non-Preferred Agents
<u>Drugs Containing a GLP-1 Receptor Agonist</u> Saxenda (<i>liraglutide</i>) Pen ^{PA, QL} Wegovy (<i>semaglutide</i>) Pen ^{PA, QL} Zepbound (<i>tirzepatide</i>) Pen ^{PA, QL}	<u>Drugs Containing a GLP-1 Receptor Agonist</u>
<u>Miscellaneous</u> Phentermine Capsule ^{PA, QL} Phentermine Tablet ^{PA, QL}	<u>Miscellaneous</u> Adipex-P (<i>phentermine</i>) Capsule ^{QL} Adipex-P (<i>phentermine</i>) Tablet ^{QL} Amphetamine Tablet ^{QL} Benzphetamine Tablet ^{QL} Diethylpropion Tablet ^{QL} Diethylpropion ER Tablet ^{QL} Evekeo (<i>amphetamine</i>) Tablet ^{QL} Lomaira (<i>phentermine</i>) Tablet ^{QL} Orlistat Capsule ^{QL} Phendimetrazine Tablet ^{QL} Phendimetrazine ER Capsule ^{QL} Xenical (<i>orlistat</i>) Capsule ^{QL}

Statewide PDL – CHC Utilization

- Utilization in CHC by scripts:

PA CHC GLP-1 Scripts SFY 24 By Drug	
Drug Name	Scripts
TRULICITY	29,396
WEGOVY	7,985
OZEMPIC	5,140
VICTOZA 3-PAK	1,032
ZEPBOUND	885
MOUNJARO	827
SAXENDA	590
VICTOZA 2-PAK	843
RYBELSUS	303
XULTOPHY 100-3.6	XX
SOLIQUA 100-33	25
LIRAGLUTIDE	XX
Total	47,048

Statewide PDL – MA Bulletin

- The most recent [MA Bulletin 2024080702](#) “Prior Authorization of Obesity Treatment Agents – Pharmacy Services” was issued on August 7, 2024, with an effective date of September 2, 2024. This MA Bulletin outlines the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Obesity Treatment Agents submitted for prior authorization.
- The CHC-MCOs are required to follow the MA Bulletin and the CHC Agreement.
- If a participant is prescribed a Glucagon-like Peptide-1 (GLP-1), the request would come to the CHC-MCO for review.

Questions/Public Comments

